ASH MPN Spotlight

Ivosidenib Demonstrates Responses in More Than 40% in Relapsed/Refractory IDH+ AML

December 16, 2017

Ivosidenib (AG-120), an IDH1 inhibitor, demonstrated an objective response rate (ORR) of 41.6% in patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to findings from a single-arm phase I study.

Pegylated Interferon Alfa-2a Active in Hydroxyurea-Resistant PV and ET

December 16, 2017

Treatment with pegylated interferon alfa-2a led to objective responses in about two-thirds of patients with hydroxyurea (Hydrea)-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia, a phase II study of salvage therapy showed.

Sotatercept in Patients With MPN-Associated Myelofibrosis and Anemia

December 16, 2017

Srdan Verstovsek, MD, of MD Anderson Cancer Center, discusses a study of sotatercept (ACE-011) alone and in combination with ruxolitinib in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.

Ropeginterferon Alfa-2b Has Long-Term Benefits in Polycythemia Vera

December 15, 2017

A novel pegylated formulation of interferon alfa-2b achieved a significantly higher rate of complete hematologic response compared with hydroxyurea (Hydrea) in patients with polycythemia vera, according to 2-year findings from the follow-up phase III CONTI-PV randomized trial.

Sotatercept Boosts Hemoglobin in MPN-Associated Myelofibrosis

December 15, 2017

The investigational activin receptor IIA ligand trap sotatercept safely increases hemoglobin levels in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis, both when used alone and in combination with ruxolitinib (Jakafi).

Nutlin Antagonist Shows Activity in Polycythemia Vera

December 14, 2017

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera.

Follow-Up Results for Ruxolitinib in the Second-Line Treatment of PV

December 12, 2017

Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.

BLU-285 Induces Responses in Patients With Systemic Mastocytosis

December 11, 2017

Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis (ASM), a rare blood disorder that originates in mast cells, according to data from an ongoing phase I trial.